Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer

Biller, Barbara; Elmslie, Robyn; Burnett, Robert; Avery, Anne C.; Dow, Steven

doi:10.1016/j.vetimm.2006.12.002

Cited by 132 publications

(154 citation statements)

References 39 publications

Supporting

Mentioning

141

Contrasting

Unclassified

Order By: Relevance

“…In dogs, a number of research articles have been published based upon changes in CD4 + and Foxp3 + proportion of cells that occur in tumors (Gereda et al, 2000;Biller et al, 2007;O'neill et al, 2009;Horiuchi et al, 2009;Rissetto et al, 2010;Biller et al, 2010;Tominaga et al, 2010). A study comparing the percentage of Tregs between healthy dogs and those with diverse tumors such as round cell tumors, sarcomas and carcinomas, showed a higher Tregs expression both in peripheral blood and tumor tissue (Biller et al, 2007).…”

Section: Discussionmentioning

confidence: 99%

“…A study comparing the percentage of Tregs between healthy dogs and those with diverse tumors such as round cell tumors, sarcomas and carcinomas, showed a higher Tregs expression both in peripheral blood and tumor tissue (Biller et al, 2007). However, some authors assert that carcinomas are associated with higher Tregs expression compared to other tumor types (O'neill et al, 2009).…”

Section: Discussionmentioning

confidence: 99%

“…Lymph node samplings were not performed on CG dogs. Based on the methods described by Biller et al (2007) Table 1. In tubes 1, 2 and 3, 1 x 10 6 cells we used.…”

Section: Methodsmentioning

confidence: 99%

“…Additionally, these cells were preferentially present in the sentinel lymph nodes of tumors (Biller et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

“…Natural Regulatory T cells express CD4 and CD25 (high affinity to interleukin-2 receptors) and are also transcribed by the Foxp3 factor (Banham et al, 2009). In dogs, Tregs were identified using specific antibodies against canine CD4 and murine Foxp3 (Biller et al, 2007;Keppel et al, 2008;Banham et al, 2009;Horiuchi et al, 2009;O'neill et al, 2009). …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Quantification of Treg cells in peripheral blood and lymph nodes of dogs with multicentric lymphoma

Anai¹,

Munhoz

Semolin³

et al. 2017

Arq. Bras. Med. Vet. Zootec.

View full text Add to dashboard Cite

Lymphoma is a malignant tumor characterized by cell proliferation of lymphoid origin and corresponds to 90% of all hematopoietic neoplasms of dogs. Regulatory T cells (Tregs) have been the target of many investigations in oncology due to their potential of down-regulating immune responses, as well as ensuring the maintenance of active mechanisms of tumor suppression. The aims of the present study were to compare the percentage of Tregs in peripheral blood between dogs with multicentric lymphoma and healthy animals, together with the percentage of Tregs in peripheral blood and lymph nodes of dogs with multicentric lymphoma. Twenty-six animals were enrolled in the study: 10 healthy dogs comprised the control group (CG) and 16 dogs with multicentric lymphoma comprised the Lymphoma Group (LG). We observed that dogs in the LG showed a significantly higher Tregs expression in peripheral blood compared to the CG. No significant difference was observed between Tregs expression in lymph nodes and peripheral blood of the LG, however. With these results, it is possible to conclude that multicentric lymphoma is a neoplasm with high Tregs expression, which poses this as a condition of interest when investigating treatments that can suppress Regulatory T cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Lymph node samplings were not performed on CG dogs. Based on the methods described by Biller et al (2007) Table 1. In tubes 1, 2 and 3, 1 x 10 6 cells we used.…”

Section: Methodsmentioning

confidence: 99%

“…Additionally, these cells were preferentially present in the sentinel lymph nodes of tumors (Biller et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Quantification of Treg cells in peripheral blood and lymph nodes of dogs with multicentric lymphoma

Anai¹,

Munhoz

Semolin³

et al. 2017

Arq. Bras. Med. Vet. Zootec.

View full text Add to dashboard Cite

show abstract

Dog Models of Naturally Occurring Cancer

Fenger

Rowell

Zapata

et al. 2016

Methods and Principles in Medicinal Chemistry

View full text Add to dashboard Cite

Studies using dogs provide an ideal solution to the gap in animal models of natural disease and translational medicine. This is evidenced by approximately 400 inherited disorders being characterized in domesticated dogs, most of which are relevant to humans. There are several hundred isolated populations of dogs (breeds) and each has vastly reduced genetic variation compared to humans; this simplifies disease mapping and pharmacogenomics. Dogs age five to eight-fold faster than humans, share environments with their owners, are usually kept until old age, and receive a high level of health care. Farseeing investigators recognized this potential and, over the last decade, developed the necessary tools and infrastructure to utilize this powerful model of human disease, including the sequencing of the dog genome in 2005. Here we review the nascent convergence of genetic and translational canine models of spontaneous disease, focusing on cancer.

show abstract

Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD‐L1 and CTLA‐4

Jiang

Zhang

et al. 2021

Advanced Science

View full text Add to dashboard Cite

Combinations of immune checkpoint therapies show encouraging results in the treatment of many human cancers. However, the higher costs and greater side effects of such combinations compared with single-agent immunotherapies limit their further applications. In this work, a novel smart agent, KN046@ 19 F-ZIF-8, is developed to overcome these limitations. KN046 is a novel recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody-Fc fusion protein, which can bind to both PD-L1 and CTLA-4 effectively. ZIF-8 is a smart delivery system, which can safely and effectively deliver KN406 to a tumor. In vitro and in vivo results demonstrate that the smart agent KN046@ 19 F-ZIF-8 not only improves the immune response rate of the antibody drug in treatment of tumors but also reduces its toxic side effects, thereby achieving excellent antitumor efficacy. This study provides an engineering strategy for clinical applications of a more effective immunotherapy.

show abstract

Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer

Cited by 132 publications

References 39 publications

Quantification of Treg cells in peripheral blood and lymph nodes of dogs with multicentric lymphoma

Quantification of Treg cells in peripheral blood and lymph nodes of dogs with multicentric lymphoma

Dog Models of Naturally Occurring Cancer

Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD‐L1 and CTLA‐4

Contact Info

Product

Resources

About